Physician profile
Ritu Thamman
NPI 1558442947
$13,155.17
in general payments reported to CMS, 2019-2025
10 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $5,543 · 2021: $5,543 · 2022: $117 · 2023: $204 · 2024: $215 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $10,280.50 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $1,270.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $805.50 | 2020-2021 | |
| Abbott Laboratories | $203.67 | 2023 | Optis |
| Neosoft, LLC | $129.73 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.34 | 2024 | |
| Heartflow, INC. | $110.53 | 2025 | |
| Ge Healthcare | $98.88 | 2025 | |
| Medtronic, INC. | $92.80 | 2024 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $40.94 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Thamman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.